AVI BioPharma names chief executive
Chris Garabedian joins US biopharmaceutical firm from Celgene
Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.
Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.
He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.
‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.
You may also like
Finance
European life sciences investors kick off 2026 with targeted bets on immunity, oncology and metabolic health
From thymus regeneration and ECM-targeted oncology to fast-scaling metabolic health technology, three European companies secure fresh capital as investors double down on differentiated science with clear commercial momentum
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Biologics at a turning point: complexity, AI and the road to 2026
Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena